Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ronald de Wit

Showing results (71-80 of 204) with videos related to

Pageof 21
Sort By:
International Journal of Hyperthermia : the Official Journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group|August 19, 2007
Weekly systemic cisplatin plus locoregional hyperthermia: an effective treatment for patients with recurrent cervical carcinoma in a previously irradiated areaMartine Franckena, Ronald De Wit, Anca C Ansink, et al.
Therapeutic Advances in Medical Oncology|June 9, 2022
Neutropenia, neutrophilia, and neutrophil-lymphocyte ratio as prognostic markers in patients with metastatic castration-resistant prostate cancerAlexander Meisel, Ronald de Wit, Stephane Oudard, et al.
Acta Oncologica (Stockholm, Sweden)|September 3, 2013
Markedly increased incidence and improved survival of testicular cancer in the NetherlandsRob H A Verhoeven, Henrike E Karim-Kos, Jan Willem W Coebergh, et al.
European Urology|December 1, 2018
PD-L1 Antibody Comparison in Urothelial CarcinomaMaud Rijnders, Astrid A M van der Veldt, Tahlita C M Zuiverloon, et al.
European Urology Oncology|August 15, 2019
Cost-effectiveness of Pembrolizumab for Patients with Advanced, Unresectable, or Metastatic Urothelial Cancer Ineligible for Cisplatin-based TherapyKarl Patterson, Vimalanand Prabhu, Ruifeng Xu, et al.
European Urology|August 17, 2006
Predicting retroperitoneal histology in postchemotherapy testicular germ cell cancer: a model update and multicentre validation with more than 1000 patientsYvonne Vergouwe, Ewout W Steyerberg, Richard S Foster, et al.
European Urology|August 3, 2015
Reply to Masaki Shiota and Akira Yokomizo's Letter to the Editor re: Robert J. van Soest, Ellen S. de Morrée, Charlotte F. Kweldam, et al. Targeting the Androgen Receptor Confers In Vivo Cross-resistance Between Enzalutamide and Docetaxel, But Not Cabazitaxel, in Castration-resistant Prostate Cancer. Eur Urol 2015;67:981-5Robert J van Soest, Ellen S de Morrée, Charlotte F Kweldam, et al.
Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences|June 3, 2023
Validation of an LC-MS/MS method for simultaneous quantification of abiraterone, enzalutamide and darolutamide in human plasmaStefan A J Buck, Peter de Bruijn, Inge M Ghobadi-Moghaddam-Helmantel, et al.
European Urology|July 1, 2011
Evaluating the value of number of cycles of docetaxel and prednisone in men with metastatic castration-resistant prostate cancerGregory R Pond, Andrew J Armstrong, Brian A Wood, et al.
Molecular Oncology|December 11, 2023
Flow-based immunomagnetic enrichment of circulating tumor cells from diagnostic leukapheresis productMichiel Stevens, Anouk Mentink, Frank A W Coumans, et al.
Pageof 21

Showing results (71-80 of 204) with videos related to

Sort By:
Pageof 21
International Journal of Hyperthermia : the Official Journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group|August 19, 2007
Weekly systemic cisplatin plus locoregional hyperthermia: an effective treatment for patients with recurrent cervical carcinoma in a previously irradiated areaMartine Franckena, Ronald De Wit, Anca C Ansink, et al.
Therapeutic Advances in Medical Oncology|June 9, 2022
Neutropenia, neutrophilia, and neutrophil-lymphocyte ratio as prognostic markers in patients with metastatic castration-resistant prostate cancerAlexander Meisel, Ronald de Wit, Stephane Oudard, et al.
Acta Oncologica (Stockholm, Sweden)|September 3, 2013
Markedly increased incidence and improved survival of testicular cancer in the NetherlandsRob H A Verhoeven, Henrike E Karim-Kos, Jan Willem W Coebergh, et al.
European Urology|December 1, 2018
PD-L1 Antibody Comparison in Urothelial CarcinomaMaud Rijnders, Astrid A M van der Veldt, Tahlita C M Zuiverloon, et al.
European Urology Oncology|August 15, 2019
Cost-effectiveness of Pembrolizumab for Patients with Advanced, Unresectable, or Metastatic Urothelial Cancer Ineligible for Cisplatin-based TherapyKarl Patterson, Vimalanand Prabhu, Ruifeng Xu, et al.
European Urology|August 17, 2006
Predicting retroperitoneal histology in postchemotherapy testicular germ cell cancer: a model update and multicentre validation with more than 1000 patientsYvonne Vergouwe, Ewout W Steyerberg, Richard S Foster, et al.
European Urology|August 3, 2015
Reply to Masaki Shiota and Akira Yokomizo's Letter to the Editor re: Robert J. van Soest, Ellen S. de Morrée, Charlotte F. Kweldam, et al. Targeting the Androgen Receptor Confers In Vivo Cross-resistance Between Enzalutamide and Docetaxel, But Not Cabazitaxel, in Castration-resistant Prostate Cancer. Eur Urol 2015;67:981-5Robert J van Soest, Ellen S de Morrée, Charlotte F Kweldam, et al.
Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences|June 3, 2023
Validation of an LC-MS/MS method for simultaneous quantification of abiraterone, enzalutamide and darolutamide in human plasmaStefan A J Buck, Peter de Bruijn, Inge M Ghobadi-Moghaddam-Helmantel, et al.
European Urology|July 1, 2011
Evaluating the value of number of cycles of docetaxel and prednisone in men with metastatic castration-resistant prostate cancerGregory R Pond, Andrew J Armstrong, Brian A Wood, et al.
Molecular Oncology|December 11, 2023
Flow-based immunomagnetic enrichment of circulating tumor cells from diagnostic leukapheresis productMichiel Stevens, Anouk Mentink, Frank A W Coumans, et al.
Pageof 21